Allez Health, a company specializing in biosensor technology, raises $60 million in funding.

Allez Health, previously known as Zense-Life Inc. and based in California, recently announced that it has secured $60 million in Series A+ financing. The funding round was led by strategic investor Osang Healthcare Co., Ltd., with participation from existing investors. Allez Health specializes in a continuous glucose monitoring biosensor platform that utilizes sensor technology to enhance a patient’s performance by analyzing datasets related to various health conditions.

The funds raised will be utilized to support operations, facilitate regulatory approval filings, scale manufacturing, and expedite clinical trials. The leadership team and cofounders of Allez Health have previously worked at Dexcom. For instance, the company’s CEO, Leif Bowman, was a senior director of marketing at Dexcom, while the Chief Technology Officer, Robert Boock, was the lead inventor of Dexcom G4 CGM. Ted Zhang, the Chief Science Officer, played a pivotal role in the development of Dexcom G4’s sensor membrane.

Bowman emphasized the importance of individual-centric health solutions and expressed the company’s commitment to providing a sensor that combines accessibility, affordability, and reliable performance. Allez Health aims to offer a product that prioritizes both price and performance when it comes to an individual’s health.

In the market, Dexcom recently received FDA clearance in March for its over-the-counter continuous glucose monitoring (CGM) solution, Stelo. This wearable biosensor, designed to be worn on the back of the upper arm, has a battery life of up to two weeks and aids in detecting normal and abnormal glucose levels. Additionally, Kakao Healthcare introduced its AI-enabled diabetes management app, PASTA, which connects to CGM devices like CareSens Air by i-SENS and Dexcom’s G7, as well as the Mallya smart cap for insulin pens.